Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma.Подробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Safety and Efficacy of Mosunetuzumab Plus Polatuzumab VedotinПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCLПодробнее

Combination of mosunetuzumab with CHOP in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Polatuzumab vedotin plus rituximab and lenalidomide in DLBCL: a Phase Ib/II studyПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Updated results from EPCORE NHL-2: epcoritamab plus GemOx in patients with R/R DLBCLПодробнее

SUNMO trial design: mosunetuzumab plus polatuzumab vedotin vs R-GemOx in R/R NHLПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumabПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее